Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Funapide - Flexion Therapeutics

Drug Profile

Funapide - Flexion Therapeutics

Alternative Names: FX 301; TV 45070; XEN-402; XPF 002; XPF-001

Latest Information Update: 04 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xenon Pharmaceuticals
  • Developer Flexion Therapeutics; Teva Pharmaceutical Industries; Xenon Pharmaceuticals
  • Class Benzodioxoles; Fluorobenzenes; Furans; Indoles; Non-opioid analgesics; Small molecules; Spiro compounds; Vascular disorder therapies
  • Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Erythromelalgia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuropathic pain; Postherpetic neuralgia
  • Phase I Postoperative pain
  • Discontinued Dental pain; Erythromelalgia; Musculoskeletal pain; Pain

Most Recent Events

  • 04 Aug 2021 Chemical structure information added
  • 15 Mar 2021 Phase-I clinical trials in Postoperative pain in USA (Parenteral) (NCT04826328)
  • 03 Mar 2021 USFDA approves IND application for FX 301 in Postoperative pain
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top